BiotechTube

Lesigercept + Placebo

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Allergic Diseases

Conditions

Allergic Diseases, Chronic Spontaneous Urticaria (CSU)

Trial Timeline

Mar 31, 2026 → Jul 24, 2027

NCT ID
NCT07415551

About Lesigercept + Placebo

Lesigercept + Placebo is a phase 2 stage product being developed by Yuhan for Allergic Diseases. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07415551. Target conditions include Allergic Diseases, Chronic Spontaneous Urticaria (CSU).

What happened to similar drugs?

20 of 20 similar drugs in Allergic Diseases were approved

Approved (20) Terminated (3) Active (0)
✅placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
✅ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
✅Cetirizine + LoratadineJohnson & JohnsonApproved
✅Budesonide + PlaceboAstraZenecaApproved
✅Ciclesonide nasal spray + placebo Azelastine + Ciclesonide nasal spray + AzelastineAstraZenecaApproved
✅epinastine HCL and olopatadine HCLMerckApproved
✅Placebo + Montelukast + Fluticasone propionateMerckApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07415551Phase 2Recruiting

Competing Products

20 competing products in Allergic Diseases

See all competitors
ProductCompanyStageHype Score
BriquilimabJasper TherapeuticsPhase 1
11
LY3650150 + Placebo + Standard therapy for INCSEli LillyPhase 3
47
YH35324 + Omalizumab + PlaceboYuhanPhase 1
29
Bilastine + Desloratadine + PlaceboYuhanPhase 3
40
ASP2390 + PlaceboAstellas PharmaPhase 1
33
ASP4070 + PlaceboAstellas PharmaPhase 2
35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placeboShionogiPhase 2
35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + PlaceboOno PharmaceuticalPhase 2
35
Prednisolone + VoriconazoleCiplaPhase 2/3
38
placebo, isotonic ciclesonide, hypotonic ciclesonideSumitomo PharmaApproved
35
ciclesonide nasal aerosol + ciclesonide nasal spraySumitomo PharmaApproved
43
ciclesonide hydrofluoroalkane (HFA) nasal aerosol + mometasone nasal inhalationSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40
ciclesonide nasal aerosol + mometasone Aqueous (AQ) nasal spraySumitomo PharmaPhase 1
29
ciclesonide + mometasoneSumitomo PharmaPhase 3
40
DSP-3025 + PlaceboSumitomo PharmaPhase 1
29
ciclesonide nasal aerosol + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA 80 mcg + Ciclesonide HFA 160 mcg + PlaceboSumitomo PharmaPhase 3
40
Ciclesonide HFA Nasal Aerosol 320 mcg + Ciclesonide HFA Nasal Aerosol 160 mcg + HFA Nasal Aerosol placebo + Ciclesonide Aqueous Nasal Spray 200 mcg + AQ Nasal Spray Placebo + Placebo plus Dexamethasone HFA + Placebo AQ plus Dexamethasone 6 mgSumitomo PharmaPhase 3
40
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + PlaceboSumitomo PharmaPhase 3
40